Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19
March 19th 2020
The ESH task force on COVID-19 is in contact with experts and clinicians involved in care of COVID-19 patients and is continuously evaluating new information. Currently, we confirm our previous recommendations from last week, March 19th, 2020:
Previous text unchanged
Currently there is no clear evidence that hypertension per se is associated with an increased risk of infection by COVID-19. Therefore, patients with hypertension should apply the same precautions as subjects of the same age category and with the same profile of comorbidities (https://www.ecdc.europa.eu/en/novel-coronavirus-china).
In stable patients with COVID-19 infections or at risk for COVID-19 infections, treatment with ACEIs and ARBs should be executed according to the recommendations in the 2018 ESC/ESH guidelines.1
The currently available data on COVID-19 infections do not a support a differential use of RAS blockers (ACEI or ARBs) in COVID-19 patients.
In COVID-19 patients with severe symptoms or sepsis, RAS blockers and other blood pressure lowering drugs should be used or discontinued on a case-by-case basis, taking into account current guidelines.
Further research analysing the continuously increasing data on the impact of hypertension and blood pressure lowering drugs, particularly RAS blockers, on the clinical course of COVID-19 infections is warranted.
A note of caution!
This statement reflects current evidence at time of release and may need updating according to novel evidence.